Stock Ratings / Health Care / ISPC / earnings

BIAF (32) ONMD (29) MXCT (30) NRC (65) ⌘ Pro Terminal →

iSpecimen Inc. (ISPC) Next Earnings Date & Expected ±12.5% Move

Q: When is ISPC's next earnings date?

Based on SEC filing cadence, iSpecimen Inc. (ISPC)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is ISPC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ISPC, spanning a range between $1 and $0.89.

$0.79 -9.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.78

iSpecimen Inc. (ISPC) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.78 (-1.87%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ISPC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY ISPC SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 11.2% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.13-18.6% Next Q

Q2 (-2Q)

Grade D$0.92-10.9% Next Q

Q3 (-1Q)

Grade D$0.82-3.7% Next Q

Current

Grade D-$0.79-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ISPC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ISPC currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($0.83) forces dealer call-delta covering toward $34.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ISPC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ISPC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

ISPC Quantitative Pre-Earnings Setup: 39/100

Trailing EPS: $4.25 • YoY Revenue Growth: -65%

Model Bullish Setup (39/100)Model Risk Weight (61/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.9M	-$10.5M	-$4.2M	11.2%
FY 2024	2024-12-31	$9.3M	-$12.5M	-$8.3M	45%
FY 2023	2023-12-31	$9.9M	-$11.1M	-$5.8M	11.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ISPC)

✓Walkthrough of ISPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ISPC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.89%⚡ TESTING RESISTANCE

2026-10-30O $0.85H $0.87L $0.75C $0.79VOL 523.2K

RES: $0.98SUP: $0.76SMA50: $1.23SMA200: $4.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ISPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ISPC Butterfly Map → + Track ISPC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ISPC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ISPC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ISPC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ISPC)

Health Care Rank #688 of 1016 ⚔️ BIAF vs ISPC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ISPC vs. BIAF, ONMD, MXCT, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, iSpecimen Inc. (ISPC) ranks #688 by composite RQD confidence (39/100, grade D-) and #998 by equity capitalization ($2.0M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with ISPC at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ISPC ACTIVE iSpecimen Inc.	D-	39/100	—	11.2%	-35.0%	-9.35%	$2.0M	Benchmark Subject
BIAF bioAffinity Technologies Inc.	E	32/100	—	—	-35.0%	-3.50%	$3.9M	/biaf-vs-ispc →
ONMD OneMedNet Corp (Class A)	E	29/100	—	-30.0%	-35.0%	-2.02%	$26.3M	/onmd-vs-ispc →
MXCT MaxCyte Inc.	E	30/100	—	96.0%	-27.1%	+1.17%	$178.5M	/mxct-vs-ispc →
NRC NRC Health	C	65/100	44.8x	—	21.0%	+0.09%	$519.6M	/nrc-vs-ispc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001558569

In its most recent audited fiscal period (FY2025, filed 2025-12-31), iSpecimen Inc. (ISPC) reported GAAP revenue of $1.9M (-79.2% vs. FY2024 revenue of $9.3M , and -80.6% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$4.2M, and free cash flow of -$4.2M (+48.9% YoY). On the balance sheet, ISPC closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.9M	-$10.5M	-$4.2M	-$4.2M	$9.5M	—
FY2024 (FY)	2024-12-31	$9.3M	-$12.5M	-$8.3M	-$8.3M	$9.4M	—
FY2023 (FY)	2023-12-31	$9.9M	-$11.1M	-$5.8M	-$5.8M	—	—

3. ISPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, iSpecimen Inc. (NASDAQ: ISPC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.79 (-9.35% 1D, market cap $2.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ISPC ranks #688 in composite RQD confidence.

How does ISPC compare to BIAF and ONMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $26.3M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ISPC?

Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ISPC trading relative to its 50-day, 200-day, and 52-week technical levels?

ISPC last traded at $0.79 (-9.35% on volume of 2,593,810 shares), positioning the stock -35.77% below its 50-day simple moving average ($1.23) and -83.74% below its 200-day simple moving average ($4.86). Across its 52-week range of $0.75 to $32.96, ISPC sits at the 0.1% percentile with a 14-day RSI of 31.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.89).

ISPC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ISPC's next earnings date?

Based on SEC filing cadence, iSpecimen Inc. (ISPC)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ISPC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ISPC, spanning a range between $1 and $0.89.

Direct Sub-Reports: ISPC RQD Cockpit ISPC 12M Forecast ISPC Earnings & Move ISPC Dividends & DRIP ISPC Insiders & 13F ISPC Whale Options ISPC Profit Sankey ISPC News & Why